Modeling WWOX loss of function in vivo: What have we learned?

Mayur Tanna, Rami I. Aqeilan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


The WW domain-containing oxidoreductase (WWOX) gene encompasses a common fragile sites (CFS) known as FRA16D, and is implicated in cancer. WWOX encodes a 46kDa adaptor protein, which contains two N-terminal WW-domains and a catalytic domain at its C-terminus homologous to short-chain dehydrogenase/reductase (SDR) family proteins. A high sequence conservation of WWOX orthologues from insects to rodents and ultimately humans suggest its significant role in physiology and homeostasis. Indeed, data obtained from several animal models including flies, fish, and rodents demonstrate WWOX in vivo requirement and that its deregulation results in severe pathological consequences including growth retardation, post-natal lethality, neuropathy, metabolic disorders, and tumorigenesis. Altogether, these findings set WWOX as an essential protein that is necessary to maintain normal cellular/physiological homeostasis. Here, we review and discuss lessons and outcomes learned from modeling loss of WWOX expression in vivo.

Original languageAmerican English
Article number420
JournalFrontiers in Oncology
Issue numberOCT
StatePublished - 10 Oct 2018

Bibliographical note

Funding Information:
The Aqeilan lab is funded by the European Research Council (ERC)-Consolidator Grant (grant agreement No. 682118), Israel science foundation grant (grant agreement No. 15/1574) and the Alex U. Soyka Pancreatic Cancer Research grant (CFHU).

Publisher Copyright:
© 2018 Frontiers Media S.A. All Rights Reserved.


  • Cancer
  • Drosophila
  • Epilepsy
  • Knockout
  • Metabolism
  • Model organisms
  • Mouse
  • Zebrafish


Dive into the research topics of 'Modeling WWOX loss of function in vivo: What have we learned?'. Together they form a unique fingerprint.

Cite this